NovoCure (NVCR) Cash from Investing Activities (2014 - 2026)

NovoCure has disclosed Cash from Investing Activities across 13 years of filings, most recently posting $7.7 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $7.7 million, up 219.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $451.5 million (up 214.9% YoY), and the FY2025 annual result was $437.3 million, up 411.8% from the prior year.
• Cash from Investing Activities came in at $7.7 million for Q1 2026 at NovoCure, down from $336.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $336.3 million in Q4 2025 to a low of -$374.4 million in Q2 2024.
• The 5-year median for Cash from Investing Activities is $10.2 million (2024), against an average of $20.5 million.
• Across the five-year window, Cash from Investing Activities surged 6049.47% in 2022 and sank 2594.39% in 2024, its largest moves.
• NovoCure's Cash from Investing Activities stood at -$128.1 million in 2022, then soared by 176.92% to $98.5 million in 2023, then sank by 122.55% to -$22.2 million in 2024, then surged by 1614.23% to $336.3 million in 2025, then sank by 97.7% to $7.7 million in 2026.
• The last three Cash from Investing Activities figures came in at $7.7 million (Q1 2026), $336.3 million (Q4 2025), and $71.4 million (Q3 2025), per Business Quant data.